CO2023009368A2 - Cocristal de un inhibidor de cdk - Google Patents

Cocristal de un inhibidor de cdk

Info

Publication number
CO2023009368A2
CO2023009368A2 CONC2023/0009368A CO2023009368A CO2023009368A2 CO 2023009368 A2 CO2023009368 A2 CO 2023009368A2 CO 2023009368 A CO2023009368 A CO 2023009368A CO 2023009368 A2 CO2023009368 A2 CO 2023009368A2
Authority
CO
Colombia
Prior art keywords
cocrystal
cdk inhibitor
relates
cdk7
disorders
Prior art date
Application number
CONC2023/0009368A
Other languages
English (en)
Inventor
Uday Bhat
Ranadeep Bokalial
Sangamesh Eshwarappa Badiger
Krishnaswamy Devanathan
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of CO2023009368A2 publication Critical patent/CO2023009368A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere al compuesto de fumarato de fórmula (I) y su forma cristalina y métodos para su preparación. (I) La invención también se relaciona con preparaciones adecuadas para usos farmacéuticos para el tratamiento de diversas enfermedades o trastornos mediados por CDK7, particularmente cáncer u otras enfermedades proliferativas.
CONC2023/0009368A 2020-12-18 2023-07-14 Cocristal de un inhibidor de cdk CO2023009368A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
CO2023009368A2 true CO2023009368A2 (es) 2023-09-29

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009368A CO2023009368A2 (es) 2020-12-18 2023-07-14 Cocristal de un inhibidor de cdk

Country Status (17)

Country Link
US (1) US20240059669A1 (es)
EP (1) EP4263534A1 (es)
JP (1) JP2023554492A (es)
KR (1) KR20230159363A (es)
CN (1) CN116685326A (es)
AU (1) AU2021402415A1 (es)
CA (1) CA3202198A1 (es)
CL (1) CL2023001753A1 (es)
CO (1) CO2023009368A2 (es)
CR (1) CR20230261A (es)
DO (1) DOP2023000126A (es)
EC (1) ECSP23054131A (es)
IL (1) IL303738A (es)
MX (1) MX2023007218A (es)
PE (1) PE20231441A1 (es)
TW (1) TW202241881A (es)
WO (1) WO2022130304A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024970B (zh) 2015-06-04 2021-10-01 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物

Also Published As

Publication number Publication date
CR20230261A (es) 2023-10-04
US20240059669A1 (en) 2024-02-22
CA3202198A1 (en) 2022-06-23
CN116685326A (zh) 2023-09-01
IL303738A (en) 2023-08-01
MX2023007218A (es) 2023-07-27
KR20230159363A (ko) 2023-11-21
WO2022130304A1 (en) 2022-06-23
AU2021402415A1 (en) 2023-07-06
PE20231441A1 (es) 2023-09-14
JP2023554492A (ja) 2023-12-27
EP4263534A1 (en) 2023-10-25
TW202241881A (zh) 2022-11-01
CL2023001753A1 (es) 2024-02-02
DOP2023000126A (es) 2023-11-30
ECSP23054131A (es) 2023-09-29

Similar Documents

Publication Publication Date Title
BR112022010383A2 (pt) Compostos tricíclicos substituídos
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
CO2023013356A2 (es) Compuestos para la inhibición de nlrp3 y usos de estos
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
CR20190124A (es) Inhibidores de ssao de aminopirimidina
MX2019012756A (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats.
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CU24671B1 (es) Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
ECSP23054131A (es) Cocristal de un inhibidor de cdk
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
BRPI0509653A (pt) inibidores cinesina mitótica
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
AR022857A1 (es) Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa